Literature DB >> 25127205

Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication.

Deborah Taira Juarez1, Carolyn Ma, Audrey Kumasaka, Reid Shimada, James Davis.   

Abstract

The objectives of this study were to describe patient characteristics and types of medications taken by those with poor glycemic control (A1c>7%) despite being adherent to antidiabetic medications. This is a retrospective analysis of administrative data from adult patients with diabetes enrolled in a large health plan in Hawaii (n=21,267 observations for 11,013 individuals) and adherent to their antidiabetic medications. Multivariable logistic regressions were estimated to determine characteristics and types of medications associated with poor glycemic control. Separate models were estimated to examine category of medication (insulin only, 1 oral medication, multiple oral medications, both oral medications and insulin) and specific therapeutic class of oral antidiabetic medications. Despite being adherent to their medications, 56.1% of patients had poor glycemic control. Compared to patients taking combination sulfonylureas, patients had a higher odds of having A1c>7% for all other oral diabetic medications, with odds ratios ranging from OR=2.07 for sulfonylureas alone to OR=1.33 for combination DPP-4 inhibitors. More than half of patients in this study had poor A1c control despite being adherent to their medications. This suggests that physicians, pharmacists, and other providers may need to monitor treatment regimens more carefully, encourage healthy behaviors, and intensify pharmacological treatment as needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25127205      PMCID: PMC4150373          DOI: 10.1089/pop.2013.0099

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  22 in total

1.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  Reasons for not intensifying medications: differentiating "clinical inertia" from appropriate care.

Authors:  Monika M Safford; Richard Shewchuk; Haiyan Qu; Jessica H Williams; Carlos A Estrada; Fernando Ovalle; Jeroan J Allison
Journal:  J Gen Intern Med       Date:  2007-10-24       Impact factor: 5.128

5.  Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort.

Authors:  S H Song; C A Hardisty
Journal:  QJM       Date:  2009-09-04

6.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

Review 7.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

Review 8.  Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus.

Authors:  E Vermeire; J Wens; P Van Royen; Y Biot; H Hearnshaw; A Lindenmeyer
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

9.  Adherence to oral hypoglycemic agents in Hawaii.

Authors:  Rachel Lee; Deborah A Taira
Journal:  Prev Chronic Dis       Date:  2005-03-15       Impact factor: 2.830

10.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

View more
  12 in total

1.  Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need?

Authors:  Ronald J Pettis; Douglas Muchmore; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2018-12-07

2.  Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses.

Authors:  John E Schneider; Anjani Parikh; Ivana Stojanovic
Journal:  J Health Econ Outcomes Res       Date:  2018-02-20

3.  Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA-DM cohort study.

Authors:  Ryosuke Sakai; Yoshitaka Hashimoto; Emi Ushigome; Takuro Okamura; Masahide Hamaguchi; Masahiro Yamazaki; Yohei Oda; Michiaki Fukui
Journal:  J Diabetes Investig       Date:  2018-09-24       Impact factor: 4.232

4.  Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.

Authors:  Julio Rosenstock; Shira Perl; Eva Johnsson; Ricardo García-Sánchez; Stephan Jacob
Journal:  Diabetes Obes Metab       Date:  2019-06-24       Impact factor: 6.577

5.  Impact of food pattern on glycemic control among type 2 diabetic patients: a cross-sectional study in the United Arab Emirates.

Authors:  Amena Sadiya; Rama Mnla
Journal:  Diabetes Metab Syndr Obes       Date:  2019-07-16       Impact factor: 3.168

6.  Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.

Authors:  Kamlesh Khunti; Hungta Chen; Javier Cid-Ruzafa; Peter Fenici; Marilia B Gomes; Niklas Hammar; Linong Ji; Mikhail Kosiborod; Stuart Pocock; Marina V Shestakova; Iichiro Shimomura; Fengming Tang; Hirotaka Watada; Antonio Nicolucci
Journal:  Diabetes Obes Metab       Date:  2019-10-01       Impact factor: 6.577

7.  The rapid effects of sleeve gastrectomy on glucose homeostasis and resolution of diabetes mellitus.

Authors:  Emre Bozkurt; Cemal Kaya; Sinan Ömeroğlu; Onur Güven; Mehmet Mihmanlı
Journal:  Endocrinol Diabetes Metab       Date:  2020-08-30

8.  Phenolic Preservative Removal from Commercial Insulin Formulations Reduces Tissue Inflammation while Maintaining Euglycemia.

Authors:  Adam Mulka; Brianne E Lewis; Li Mao; Roshanak Sharafieh; Shereen Kesserwan; Rong Wu; Donald L Kreutzer; Ulrike Klueh
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-26

9.  Comparison of Insulin Dose Adjustments by Primary Care Physicians and Endocrinologists.

Authors:  Mayer B Davidson; Petra Duran; S Joshua Davidson; Martin Lee
Journal:  Clin Diabetes       Date:  2018-01

10.  Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.

Authors:  Geltrude Mingrone; Annieke Cg van Baar; Jacques Devière; David Hopkins; Eduardo Moura; Cintia Cercato; Harith Rajagopalan; Juan Carlos Lopez-Talavera; Kelly White; Vijeta Bhambhani; Guido Costamagna; Rehan Haidry; Eduardo Grecco; Manoel Galvao Neto; Guruprasad Aithal; Alessandro Repici; Bu'Hussain Hayee; Amyn Haji; A John Morris; Raf Bisschops; Manil D Chouhan; Naomi S Sakai; Deepak L Bhatt; Arun J Sanyal; J J G H M Bergman
Journal:  Gut       Date:  2021-02-17       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.